A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Summary

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

Timeline

Start

2024-08-26

Primary completion

2025-08-28

Completion

2026-02

Outcome

Met primary endpoint

release “positive results from the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis, in which the primary endpoint of the study was met.” xencor.com ↗

release “positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS). Obexelimab met the primary endpoint” zenasbio.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Obexelimab	Monoclonal antibody	—	Subcutaneous

Indications